{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T17:21:55Z","timestamp":1781371315433,"version":"3.54.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the <jats:italic>in vitro<\/jats:italic> activities of five oxazolidinones in parallel against the reference strains of different mycobacterial species and clinical isolates of <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (Mtb), and shed light on the differences in the efficacy of these homolog drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>The minimum inhibitory concentrations (MICs) of linezolid, tedizolid, sutezolid, delpazolid, and contezolid against 16 mycobacterial reference strains and 69 <jats:italic>M. tuberculosis<\/jats:italic> clinical isolates, including 17 drug-susceptible isolates and 52 multidrug-resistant (MDR) isolates, were determined by microplate alamarBlue assay (MABA). The intracellular killing activities of contezolid and linezolid against Mtb H37Rv were compared. In addition, mutations in the linezolid resistance-related genes (<jats:italic>rplC<\/jats:italic>, <jats:italic>rplD<\/jats:italic>, and 23S rRNA) of the Mtb clinical isolates were also analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Tedizolid exhibited the strongest inhibitory activities against the reference strains of both rapidly growing mycobacteria (RGM) and slowly growing mycobacteria (SGM), among the tested oxazolidinones. In contrast, sutezolid only manifested potent activity against reference strains of SGM. Linezolid, delpazolid, and contezolid were less active against the non-tuberculous mycobacterial references. For the Mtb clinical isolates, the antimicrobial action was ranked as: sutezolid &amp;gt; tedizolid &amp;gt; contezolid and linezolid &amp;gt; delpazolid, whereas no difference between drug-sensitive and multiple drug-resistant isolates was observed. Notably, contezolid demonstrated obviously superior intracellular antimicrobial activity than linezolid. Few strains harbored mutations in <jats:italic>rrl<\/jats:italic> gene or <jats:italic>rplD<\/jats:italic> genes, although these strains had drug susceptible profiles to linezolid.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Different oxazolidinones can have discrepant antimicrobial activity against different mycobacterial species, or have different manifestations out of cell or in cell. Understanding these differences would be helpful in choosing the appropriate drug in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.1067516","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T08:15:57Z","timestamp":1669709757000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China"],"prefix":"10.3389","volume":"9","author":[{"given":"Chenqian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guirong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmin","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"B1","year":"2022","journal-title":"Global Tuberculosis Report."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03300-2020","article-title":"World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.","volume":"57","author":"Mirzayev","year":"2021","journal-title":"Eur Respir J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e1939","DOI":"10.1128\/AAC.01939-18","article-title":"In vitro activity of tedizolid against Mycobacterium tuberculosis.","volume":"63","author":"Ruiz","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1128\/AAC.00571-06","article-title":"In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis.","volume":"50","author":"Vera-Cabrera","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1128\/AAC.00356-20","article-title":"Safety and tolerability of more than six days of tedizolid treatment.","volume":"64","author":"Mensa Vendrell","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1021\/jm950956y","article-title":"Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.","volume":"39","author":"Barbachyn","year":"1996","journal-title":"J Med Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1128\/AAC.00451-18","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of single-dose oral LCB01-0371, a novel oxazolidinone with broad-spectrum activity, in healthy volunteers.","volume":"62","author":"Cho","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1128\/AAC.00493-18","article-title":"In vitro and in vivo activities of contezolid (MRX-I) against Mycobacterium tuberculosis.","volume":"62","author":"Shoen","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-13-13","article-title":"Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages.","volume":"13","author":"Molina-Torres","year":"2014","journal-title":"Ann Clin Microbiol Antimicrob."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1128\/AAC.00723-10","article-title":"In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.","volume":"54","author":"Jeong","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/jac\/dkx367","article-title":"Safety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01-0371, in healthy male subjects.","volume":"73","author":"Choi","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijantimicag.2013.03.002","article-title":"In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates.","volume":"42","author":"Yip","year":"2013","journal-title":"Int J Antimicrob Agents."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1128\/AAC.01182-08","article-title":"Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.","volume":"53","author":"Williams","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1086\/655471","article-title":"Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.","volume":"202","author":"Wallis","year":"2010","journal-title":"J Infect Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1128\/AAC.01179-10","article-title":"Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.","volume":"55","author":"Wallis","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094462","article-title":"Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis.","volume":"9","author":"Wallis","year":"2014","journal-title":"PLoS One."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1128\/AAC.02410-14","article-title":"In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.","volume":"58","author":"Zhang","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1164\/rccm.200904-0611OC","article-title":"Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.","volume":"180","author":"Williams","year":"2009","journal-title":"Am J Respir Crit Care Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"322.e","DOI":"10.1016\/j.clinthera.2017.12.017","article-title":"Short-term Safety, tolerability, and pharmacokinetics of MRX-I, an oxazolidinone antibacterial agent, in healthy chinese subjects.","volume":"40","author":"Wu","year":"2018","journal-title":"Clin Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2181","DOI":"10.1128\/AAC.02181-16","article-title":"Single- and multiple-dose study to determine the safety, tolerability, pharmacokinetics, and food effect of oral MRX-I versus linezolid in healthy adult subjects.","volume":"61","author":"Eckburg","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1164.e","DOI":"10.1016\/j.clinthera.2019.04.025","article-title":"Tolerability and pharmacokinetics of contezolid at therapeutic and supratherapeutic doses in healthy Chinese subjects, and assessment of contezolid dosing regimens based on pharmacokinetic\/pharmacodynamic analysis.","volume":"41","author":"Wu","year":"2019","journal-title":"Clin Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10928-019-09650-7","article-title":"Concentration-response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent.","volume":"46","author":"Wu","year":"2019","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e2158","DOI":"10.1128\/AAC.02158-19","article-title":"Evaluation of the effect of contezolid (MRX-I) on the corrected QT interval in a randomized, double-blind, placebo- and positive-controlled crossover study in healthy Chinese volunteers.","volume":"64","author":"Wu","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00889-21","article-title":"A novel oxazolidinone, contezolid (MRX-I), expresses anti-Mycobacterium abscessus activity in vitro.","volume":"65","author":"Guo","year":"2021","journal-title":"Antimicrob Agents Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1128\/AAC.00165-18","article-title":"Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in China.","volume":"62","author":"Zong","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/jac\/dkr589","article-title":"SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro.","volume":"67","author":"Reddy","year":"2012","journal-title":"J Antimicrob Chemother."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1067516\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T08:16:02Z","timestamp":1669709762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1067516\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":26,"alternative-id":["10.3389\/fmed.2022.1067516"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1067516","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"article-number":"1067516"}}